缺血性卒中的代谢组学应用研究及展望

doi:10.3969/j.issn.1673-5765.2024.12.003

摘要/Abstract

摘要： 代谢组学在缺血性卒中研究中具有重要应用价值，本文综述了代谢组学方法在揭示缺血性卒中的发病机制、预测发病风险、辅助临床诊断、优化治疗策略及评估预后等方面的应用进展。研究表明：代谢组学能够揭示缺血性卒中发生发展中的多种代谢异常，为发掘病理机制提供线索；通过识别代谢生物标志物，能有效预测发病风险并为早期诊断提供支持；结合人工智能方法可构建早期诊断模型，有助于区分卒中亚型，明确不同类型卒中的代谢差异，提高诊断准确性；通过监测卒中后治疗与功能恢复过程中的代谢物变化，可揭示新的潜在治疗靶点。展望未来，代谢组学有望为缺血性卒中的个性化干预和精准医疗提供科学依据。

关键词: 缺血性卒中; 代谢组学; 脂质组学; 生物标志物

Abstract: Metabolomics has important application value in the study of ischemic stroke. This article reviews the progress of metabolomics methods in revealing the pathogenesis of ischemic stroke, predicting disease risk, assisting clinical diagnosis, optimizing treatment strategies, and evaluating prognosis. Studies have shown that metabolomics can reveal various metabolic abnormalities in the occurrence and development of ischemic stroke, providing clues for exploring pathological mechanisms. Through identifying metabolic biomarkers, it can effectively predict disease risk and help with early diagnosis. When combined with artificial intelligence to build early diagnosis models, it helps to distinguish stroke subtypes, clarify metabolic differences between different types of stroke, and improve diagnostic accuracy. By monitoring changes in metabolites during post-stroke treatment and functional recovery, it reveals new potential therapeutic targets. In the future, metabolomics is anticipated to serve as a scientific basis for personalized intervention and precision medicine in ischemic stroke.

Key words: Ischemic stroke; Metabolomics; Lipidomics; Biomarker

中图分类号:

唐奕欣, 涂汝欣, 夏健. 缺血性卒中的代谢组学应用研究及展望[J]. 中国卒中杂志, 2024, 19(12): 1376-1381.

TANG Yixin, TU Ruxin, XIA Jian. Application Research and Prospect of Metabolomics in Ischemic Stroke[J]. Chinese Journal of Stroke, 2024, 19(12): 1376-1381.

参考文献

[1] ZHOU M G，WANG H D，ZENG X Y，et al. Mortality，morbidity，and risk factors in China and its provinces，1990—2017：a systematic analysis for the global burden of disease study 2017[J]. Lancet，2019，394（10204）：1145-1158.
[2] TSAO C W，ADAY A W，ALMARZOOQ Z I，et al. Heart disease and stroke statistics—2023 update：a report from the American Heart Association[J/OL]. Circulation，2023，147（8）：e93-e621[2024-10-05]. https://doi.org/10.1161/CIR.0000000000001123.
[3] GEA J，ENRÍQUEZ-RODRÍGUEZ C J，PASCUAL-GUARDIA S. Metabolomics in COPD[J]. Arch Bronconeumol，2023，59（5）：311-321.
[4] CHUMACHENKO M S，WASEEM T V，FEDOROVICH S V. Metabolomics and metabolites in ischemic stroke[J]. Rev Neurosci，2021，33（2）：181-205.
[5] JANG C，CHEN L，RABINOWITZ J D. Metabolomics and isotope tracing[J]. Cell，2018，173（4）：822-837.
[6] HUANG X X，LI L，JIANG R H，et al. Lipidomic analysis identifies long-chain acylcarnitine as a target for ischemic stroke[J/OL]. J Adv Res，2024，61：133-149[2024-10-05]. https://doi.org/10.1016/j.jare.2023.08.007.
[7] LIU R R，LUO S W，ZHANG Y S，et al. Plasma metabolomic profiling of patients with transient ischemic attack reveals positive role of neutrophils in ischemic tolerance[J/OL]. EBioMedicine，2023，97：104845[2024-10-05]. https://doi.org/10.1016/j.jare.2023.08.007.
[8] ZHOU J，ZHANG L F，PENG J H，et al. Astrocytic LRP1 enables mitochondria transfer to neurons and mitigates brain ischemic stroke by suppressing ARF1 lactylation[J]. Cell Metab，2024，36（9）：2054-2068，e14.
[9] 王永亭，曾丽莉，吕海燕，等. 缺血性卒中病因学与发病机制研究的十年进展[J]. 中国现代神经疾病杂志，2010，10（1）：2-27.
WANG Y T，ZENG L L，LYU H Y，et al. Ten-year advance in the study on causes and pathologic mechanism of ischemic stroke[J]. Chin J Contemp Neurol Neurosurg，2010，10（1）：2-27.
[10] BARANOVICOVA E，KALENSKA D，TOMASCOVA A，et al. Time-related metabolomics study in the rat plasma after global cerebral ischemia and reperfusion：effect of ischemic preconditioning[J]. IUBMB Life，2020，72（9）：2010-2023.
[11] HOLMES M V，MILLWOOD I Y，KARTSONAKI C，et al. Lipids，lipoproteins，and metabolites and risk of myocardial infarction and stroke[J]. J Am Coll Cardiol，2018，71（6）：620-632.
[12] SPENCE J D. Cardiovascular effects of TMAO and other toxic metabolites of the intestinal microbiome[J]. J Intern Med，2023，293（1）：2-3.
[13] NIU R D，WANG H，PENG R，et al. Associations of plasma metabolites with risks of incident stroke and its subtypes in Chinese adults[J/OL]. J Am Heart Assoc，2024，13（12）：e033201[2024-10-05]. https://doi.org/10.1161/JAHA.123.033201.
[14] BARANOVICOVA E，KALENSKA D，KAPLAN P，et al. Blood and brain metabolites after cerebral ischemia
[J/OL]. Int J Mol Sci，2023，24（24）：17302[2024-10-05]. https://doi.org/10.3390/ijms242417302.
[15] HIRAYAMA A，SUGIMOTO M，SUZUKI A，et al. Effects of processing and storage conditions on charged metabolomic profiles in blood[J]. Electrophoresis，2015，36（18）：2148-2155.
[16] YU Y，WEN X，LIN J G，et al. Identification of three potential novel biomarkers for early diagnosis of acute ischemic stroke via plasma lipidomics[J/OL]. Metabolomics，2023，19（4）：32[2024-10-05]. https://doi.org/10.1007/s11306-023-01990-3.
[17] TIEDT S，BRANDMAIER S，KOLLMEIER H，et al. Circulating metabolites differentiate acute ischemic stroke from stroke mimics[J]. Ann Neurol，2020，88（4）：736-746.
[18] YOU Q，PENG Q，YU Z M，et al. Plasma lipidomic analysis of sphingolipids in patients with large artery atherosclerosis cerebrovascular disease and cerebral small vessel disease[J/OL]. Biosci Rep，2020，40（9）：BSR20201519[2024-10-05]. https://doi.org/10.1042/BSR20201519.
[19] LEE E J，KIM D J，KANG D W，et al. Targeted metabolomic biomarkers for stroke subtyping[J]. Transl Stroke Res，2024，15（2）：422-432.
[20] LI X，LI J X，YU F，et al. The untargeted metabolomics reveals differences in energy metabolism in patients with different subtypes of ischemic stroke[J]. Mol Neurobiol，2024，61（8）：5308-5319.
[21] LIEBAL U W，PHAN A N T，SUDHAKAR M，et al. Machine learning applications for mass spectrometry-based metabolomics[J/OL]. Metabolites，2020，10（6）：243[2024-10-05]. https://doi.org/10.3390/metabo10060243.
[22] PICARD M，SCOTT-BOYER M P，BODEIN A，et al. Integration strategies of multi-omics data for machine learning analysis[J]. Comput Struct Biotechnol J，2021，19：3735-3746.
[23] HUANG Y Y，GU S S，HAN Z P，et al. Cold case of thrombolysis：cold recombinant tissue plasminogen activator confers enhanced neuroprotection in experimental stroke[J/OL]. J Am Heart Assoc，2023，12（17）：e029817[2024-10-05]. https://doi.org/10.1161/JAHA.123.029817.
[24] MOTTAHEDIN A，PRAG H A，DANNHORN A，et al. Targeting succinate metabolism to decrease brain injury upon mechanical thrombectomy treatment of ischemic stroke[J/OL]. Redox Biol，2023，59：102600[2024-10-05]. https://doi.org/10.1161/JAHA.123.029817.
[25] WU C H，WU C Y，PENG L X，et al. Multi-omics approaches for the understanding of therapeutic mechanism for Huang-Qi-Long-Dan Granule against ischemic stroke[J/OL]. Pharmacol Res，2024，205：107229[2024-10-05]. https://doi.org/10.1016/j.phrs.2024.107229.
[26] NAKAMURA A，SAKAI S，TAKETOMI Y，et al. PLA2G2E-mediated lipid metabolism triggers brain-autonomous neural repair after ischemic stroke[J]. Neuron，2023，111（19）：2995-3010，e9.
[27] LI X P，XIAO Y C，HUANG Y M，et al. Lactobacillus gasseri RW2014 ameliorates hyperlipidemia by modulating bile acid metabolism and gut microbiota composition in rats[J/OL]. Nutrients，2022，14（23）：4945[2024-10-05]. https://doi.org/10.3390/nu14234945.
[28] LEE J，D’AIGLE J，ATADJA L，et al. Gut microbiota-derived short-chain fatty acids promote poststroke recovery in aged mice[J]. Circ Res，2020，127（4）：453-465.
[29] SADLER R，CRAMER J V，HEINDL S，et al. Short-chain fatty acids improve poststroke recovery via immunological mechanisms[J]. J Neurosci，2020，40（5）：1162-1173.
[30] LICARI C，TENORI L，GIUSTI B，et al. Analysis of metabolite and lipid association networks reveals molecular mechanisms associated with 3-month mortality and poor functional outcomes in patients with acute ischemic stroke after thrombolytic treatment with recombinant tissue plasminogen activator[J]. J Proteome Res，2021，20（10）：4758-4770.
[31] SIDOROV E V，XU C，GARCIA-RAMIU J，et al. Global metabolomic profiling reveals disrupted lipid and amino acid metabolism between the acute and chronic stages of ischemic stroke[J/OL]. J Stroke Cerebrovasc Dis，2022，31（4）：106320[2024-10-05]. https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106320.
[32] BECKTEL D A，FRYE J B，LE E H，et al. Discovering novel plasma biomarkers for ischemic stroke：lipidomic and metabolomic analyses in an aged mouse model[J/OL]. J Lipid Res，2024，65（9）：100614[2024-10-05]. https://doi.org/10.1016/j.jlr.2024.100614.
[33] YU F，FENG X J，LI X，et al. Association of plasma metabolic biomarker sphingosine-1-phosphate with cerebral collateral circulation in acute ischemic stroke[J/OL]. Front Physiol，2021，12：720672[2024-10-05]. https://doi.org/10.3389/fphys.2021.720672.
[34] CASTELLI F A，ROSATI G，MOGUET C，et al. Metabolomics for personalized medicine：the input of analytical chemistry from biomarker discovery to point-of-care tests[J]. Anal Bioanal Chem，2022，414（2）：759-789.
[35] BONKHOFF A K，GREFKES C. Precision medicine in stroke：towards personalized outcome predictions using artificial intelligence[J]. Brain，2022，145（2）：457-475.